Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in pediatric chronic graft versus host disease
NCT03790332Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Nov 2018
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of ibrutinib in chronic graft-versus-host disease (cGVHD), sponsored by Pharmacyclics. Started Nov 2018; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03790332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790332.